Advanced-stage prostate cancer is associated with metastasis to lymph nodes and bones
and is untreatable with chemotherapy because of poor distribution of intravenously …

Immunohistochemical Evaluation of the Relationship of PTEN Gene Expression and
Pathological Parameters in Patients with Breast C Page 1 www.SID.ir Archive of SID 1IùwÍ™›vô …

Chromosomal abnormalities in the form of deletions, duplications, inversions and
translocations are common in cancer. These changes feed the oncogenic process by …

Abstract Genetically Engineered Mouse (GEM) models are a pillar of functional cancer
research. Here we developed RapidCaP, a GEM modeling system that uses surgical …

Tumor initiating subpopulations of cancer cells, also known as cancer stem cells (CSCs)
were recently identified and characterized in prostate cancer. A well characterized murine …

[eng] The transcription factor SOX2 is a key determinant of stem cell properties, also
involved in the initiation, maintenance and progression of several human cancers. By …

It is estimated that over 238,000 men were diagnosed with prostate cancer in 2013. Prostate
cancer death is typically secondary to metastatic disease. The most common site of …

Membrane metallo-endopeptidase (MME) is responsible for the catalytic inactivation of
neuropeptide substrates and is downregulated in a significant fraction of prostate cancers …

Talins are adaptor proteins that regulate focal adhesion signaling by conjugating integrins to
the cytoskeleton. Talins directly bind and activate integrins but the mechanism by which this …

PTEN and TP53 loss are common molecular alterations in aggressive prostate cancer that
progresses to castrate resistant prostate cancer (CRPC). PTEN/TP53 loss contributes to …